Genenta Science
GNTA
3 hedge funds and large institutions have $2.29M invested in Genenta Science in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 2.52% → 2.51% (-0%)
16% less capital invested
Capital invested by funds: $2.73M → $2.29M (-$442K)
25% less funds holding
Funds holding: 4 → 3 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Bank Julius Baer & Co
Zurich,
Switzerland
| $2.06M | – | – | – |
|
|
AU
2
Algebris (UK)
London,
United Kingdom
| $225K | – | – | – |
|
3
Morgan Stanley
New York
| $2.58K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$4.13K | -700 | Closed |
|
GNTA Hedge Fund Activity: Q3 2023 in Review
3 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in Genenta Science (GNTA) for Q3 2023, worth a combined $2.29M — down 16% from $2.73M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of GNTA and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS Group, exiting entirely with an estimated $4.13K sold.
- 3 institutional investors held Genenta Science (GNTA) as of Q3 2023, down from 4 in Q2 2023.
- Funds reported $2.29M of Genenta Science stock for Q3 2023, down 16% quarter-over-quarter.
- 0 funds opened new Genenta Science positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest Genenta Science seller in Q3 2023 was UBS Group, an estimated $4.13K sold.
Based on aggregated 13F filings for Q3 2023.